致：香港交易及結算所有限公司 公司名稱: 國藥科技股份有限公司 呈交日期: 2026年3月5日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08156 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 12,800,000,000 | HKD | | 0.0125 | HKD | | 160,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 12,800,000,000 | HKD | | 0.0125 | HKD | | 160,000,000 | | ...

Group 1 - The core viewpoint of the article is that China National Pharmaceutical Technology Co., Ltd. (国药科技股份) reported a significant increase in revenue and a reduction in losses for the six months ending December 31, 2025 [1] Group 2 - The company's revenue reached HKD 26.769 million, representing a year-on-year growth of 41.65% [1] - The loss attributable to shareholders narrowed to HKD 3.681 million, a decrease of 33.23% compared to the previous year [1] - The basic loss per share was HKD 0.58 cents [1]

Financial Performance - Revenue for the six months ended December 31, 2025, was HKD 26,769,000, an increase of 41.8% compared to HKD 18,898,000 for the same period in 2024[4] - Gross profit decreased to HKD 5,319,000, down 18.2% from HKD 6,500,000 in the previous year[4] - Operating loss for the period was HKD 1,539,000, compared to a loss of HKD 1,075,000 in 2024, indicating a worsening of 43.2%[4] - Loss before tax was HKD 3,679,000, a reduction of 17.5% from HKD 4,458,000 in the prior year[4] - The total comprehensive loss for the period was HKD 4,398,000, slightly increased from HKD 4,367,000 in 2024[7] - Basic loss per share was HKD 0.58, compared to HKD 2.17 in the same period last year[7] - For the six months ending December 31, 2025, the company reported a loss attributable to shareholders of HKD 3,681,000, compared to a loss of HKD 5,513,000 for the same period in 2024, representing a 33.3% improvement in losses year-over-year[11] - The company’s total comprehensive loss for the period was HKD 4,398,000, compared to HKD 5,746,000 in the previous year, reflecting a 23.5% reduction in overall losses[11] - The basic and diluted loss per share for the six months ended December 31, 2025, was HKD 0.0058, compared to HKD 0.0218 for the same period in 2024, reflecting a significant reduction in loss per share[29] Assets and Liabilities - Non-current assets decreased to HKD 2,021,000 from HKD 2,603,000 as of June 30, 2025[8] - Current assets decreased to HKD 41,339,000 from HKD 49,133,000, primarily due to a reduction in inventory[8] - Current liabilities decreased to HKD 62,590,000 from HKD 68,376,000, reflecting improved cash management[8] - The company's total liabilities net of current liabilities increased to HKD 19,230,000 from HKD 16,640,000, indicating a growing financial burden[8] - Total assets as of December 31, 2025, amounted to HKD 43,360,000, a decrease from HKD 51,736,000 as of June 30, 2025[17] - The total liabilities as of December 31, 2025, were HKD 84,452,000, down from HKD 88,430,000 as of June 30, 2025[17] - The company’s retained earnings showed a decrease, with accumulated losses reaching HKD (2,941,295,000) as of December 31, 2025, compared to HKD (2,992,861,000) at the end of 2024, reflecting ongoing challenges in profitability[11] Cash Flow and Financing - Operating cash flow for the six months ending December 31, 2025, was HKD 1,988,000, a turnaround from an outflow of HKD (781,000) in the same period of 2024, reflecting improved operational efficiency[12] - The company generated net cash flow from financing activities of HKD 3,947,000 in the first half of 2025, compared to HKD 1,488,000 in the same period of 2024, indicating increased borrowing activity[12] - Cash and cash equivalents increased to HKD 12,881,000 as of December 31, 2025, up from HKD 3,347,000 at the end of 2024, showing a strong liquidity position[12] - The company’s interest paid decreased significantly to HKD 53,000 in the first half of 2025 from HKD 1,512,000 in the same period of 2024, indicating lower financing costs[12] - The group incurred financing costs of HKD 2,140,000 for the six months ended December 31, 2025, a decrease of 36.8% from HKD 3,383,000 in the same period of 2024[24] Operational Efficiency - The company plans to expand its market presence and product offerings, although specific details were not disclosed in the financial report[37] - The company is focusing on the "AI + business application" and healthcare sectors, integrating AI technology into key operational processes to enhance decision-making accuracy and operational efficiency[47] - Future strategies include deepening the integration of AI with core business operations and expanding into healthcare-related AI solutions and data science applications[51] Shareholder Information - The company issued 1,480,151,050 non-voting convertible preferred shares at a subscription price of HKD 0.1 per share, with a conversion ratio of 1:1 into ordinary shares[36] - Holders of the convertible preferred shares are entitled to a fixed annual dividend of 5.0% for the first five years, with the option for the company to defer payments[38] - The actual interest rate on the liability portion of the convertible preferred shares is 14.35%[39] - As of December 31, 2025, the company has issued a total of 633,693,055 ordinary shares and 1,480,151,050 non-voting convertible preferred shares, each with a par value of HKD 0.0125[59] - Holders of the convertible preferred shares are entitled to a fixed annual distribution of 5.0% for the first five years, with the first payment of HKD 7,400,755.25 deferred to December 31, 2026[61][62] Governance and Management - The board does not recommend the payment of any dividend for the six months ending December 31, 2025, consistent with the previous period[58] - The company has adopted and complied with the GEM Listing Rules Appendix C1 Corporate Governance Code, with some deviations noted[84] - The board is composed of executive directors Zhao Shannen and Guo Shuyi, along with independent non-executive directors Liu Fei, Xiang Bilun, Diao Zhiqiang, and Yu Bingming[90] - The Audit Committee consists of four independent non-executive directors, with Mr. Liu Fei appointed as the chairman[88] - The Audit Committee has reviewed the unaudited results for the six months ended December 31, 2025, and confirmed compliance with applicable accounting standards[88] Staffing and Employment - The company employs 32 staff members in Hong Kong and China as of December 31, 2025, with compensation based on performance and market trends[65] Market and Competitive Landscape - There were no significant investments, acquisitions, or disposals related to subsidiaries, associates, or joint ventures during the six months ending December 31, 2025[63] - The company has not engaged in any arrangements that would allow directors or executives to benefit from purchasing shares or bonds during the reporting period[71] - There are no significant events affecting the company since the end of the reporting period[66] - There were no competitive interests held by directors, major shareholders, or their close associates in any business that directly or indirectly competes with the group as of December 31, 2025[80]

Financial Performance - The company reported revenue of HKD 26,769,000 for the six months ended December 31, 2025, representing a 41.8% increase from HKD 18,898,000 in the same period of 2024[6]. - Gross profit for the same period was HKD 5,319,000, down 18.2% from HKD 6,500,000 year-over-year[6]. - Operating loss increased to HKD 1,539,000 compared to a loss of HKD 1,075,000 in the previous year, indicating a worsening operational performance[6]. - The company reported a loss before tax of HKD 3,679,000, an improvement from a loss of HKD 4,458,000 in the prior year[6]. - Total comprehensive loss for the period was HKD 4,398,000, slightly higher than HKD 4,367,000 in the same period last year[9]. - Basic loss per share was HKD 0.58, compared to HKD 2.17 in the previous year, indicating a significant reduction in loss per share[9]. - For the six months ending December 31, 2025, the company reported a loss of HKD 3,681,000, compared to a loss of HKD 5,513,000 for the same period in 2024, indicating a 33.3% improvement in losses year-over-year[13]. - The company reported a comprehensive loss of HKD 4,398,000 for the six months ending December 31, 2025, compared to a comprehensive loss of HKD 5,746,000 for the same period in 2024, reflecting a 23.5% improvement[13]. - The group reported a loss before tax of HKD 3,679,000 for the six months ended December 31, 2025, compared to a loss of HKD 4,458,000 for the same period in 2024, indicating a 17.4% improvement[27]. - The company reported a loss attributable to shareholders of HKD 3,700,000, an improvement from a loss of HKD 5,500,000 in the previous year[54]. Assets and Liabilities - Non-current assets decreased to HKD 2,021,000 from HKD 2,603,000 as of June 30, 2025[10]. - Current assets decreased to HKD 41,339,000 from HKD 49,133,000, reflecting a decline in liquidity[10]. - Current liabilities decreased to HKD 62,590,000 from HKD 68,376,000, indicating improved management of short-term obligations[10]. - The company's total equity attributable to shareholders showed a capital deficit of HKD 41,153,000, worsening from HKD 36,868,000 in the previous period[12]. - Total assets as of December 31, 2025, amounted to HKD 43,360,000, while total liabilities were HKD 84,452,000, resulting in a debt-to-asset ratio of approximately 194.0%[18]. - The group’s total classified liabilities in the supply chain services segment were HKD 32,183,000 as of December 31, 2025[18]. - The group’s total liabilities increased from HKD 88,430,000 as of June 30, 2025, to HKD 84,452,000 as of December 31, 2025, indicating a reduction in overall liabilities[19]. - The company has a provision for bad debts amounting to HKD 10,830 million, which is 30.4% of total accounts receivable[34]. - The aging analysis of accounts receivable shows that HKD 10,145 million is overdue by more than one year, representing 35.7% of total accounts receivable[35]. - Total accounts payable as of December 31, 2025, was HKD 31,887 million, down 23.2% from HKD 41,538 million as of June 30, 2025[36]. Cash Flow and Financing - The company's cash and cash equivalents increased to HKD 12,881,000 as of December 31, 2025, up from HKD 3,347,000 at the end of 2024, representing a significant increase of 284.5%[14]. - Operating cash flow for the six months ending December 31, 2025, was HKD 1,988,000, compared to an outflow of HKD 781,000 in the same period of 2024, marking a turnaround in cash flow performance[14]. - The company raised HKD 4,000,000 in new borrowings during the financing activities for the six months ending December 31, 2025, compared to HKD 3,000,000 in the previous year, reflecting a 33.3% increase in financing activities[14]. - The net cash flow from financing activities for the six months ending December 31, 2025, was HKD 3,947,000, compared to HKD 1,488,000 in the same period of 2024, indicating a 165.5% increase[14]. - The group incurred financing costs of HKD 2,140,000 for the six months ended December 31, 2025, down from HKD 3,383,000 in the same period of 2024, reflecting a 36.7% reduction[26]. Shareholder Information - The company issued 1,480,151,050 non-voting convertible preferred shares at a subscription price of HKD 0.1 per share, completed on November 15, 2024[38]. - Holders of the convertible preferred shares are entitled to a fixed annual dividend of 5.0% for the first five years, with payments made annually[40]. - The convertible preferred shares will pay a fixed annual dividend of 5.0% for the first five years, with a total payment of HKD 7,400,755.25 deferred to December 31, 2026[63][64]. - Major shareholders include Integrated Asset Management (Asia) Limited with approximately 50.77% of ordinary shares and 147.16% of preferred shares[74]. - Creative Big Limited, owned by Mr. Zhao, holds 547,609,590 non-voting convertible preferred shares, representing 86.42% of that class[74]. - Quantum Worldwide Investment Limited holds 150,000,000 ordinary shares, accounting for 23.67%[74]. Corporate Governance - The company has adopted and complied with the GEM Listing Rules Appendix C1 Corporate Governance Code, with some deviations noted[86]. - The Audit Committee, consisting of four independent non-executive directors, has reviewed the unaudited results for the six months ending December 31, 2025, and confirmed compliance with applicable accounting standards[90]. - The company has appointed new members to the Compensation Committee and Nomination Committee, including Ms. Guo Shuyi and Mr. Liu Fei as members[87]. - The roles of Chairman and CEO are currently held by executive directors, which the board believes benefits the company's business outlook and management[86]. - The company will periodically review and update its corporate governance practices to comply with GEM Listing Rules as deemed appropriate[88]. - The company has adopted a code of conduct for securities trading by directors, confirming compliance during the review period[89]. - The board of directors consists of executive directors Zhao Shanneng and Guo Shuyi, along with independent non-executive directors Liu Fei, Xiang Bilun, Diao Zhiqiang, and Yu Bingming[92]. Strategic Focus - The company is focusing on the "AI + business application" and healthcare sales sectors, integrating AI technology into key operational processes[49]. - Future strategies include enhancing AI integration in core business areas and expanding into healthcare-related AI solutions and data science applications[53]. - No significant investments or acquisitions were made in subsidiaries, associates, or joint ventures during the six months ending December 31, 2025[65]. - There are no future plans for significant investments or capital assets as of the reporting date, with management monitoring market conditions[66]. Employee Information - The company has 32 employees in Hong Kong and China as of December 31, 2025, with compensation based on performance and market trends[67]. Director Changes - Dr. Cheng Yan-jie resigned as a non-executive director during the annual general meeting held on December 19, 2025[84]. - Mr. Diao Zhiqiang and Mr. Yu Bingming were elected as independent non-executive directors during the same meeting[84]. - There were no changes in director information that required disclosure under GEM Listing Rules during the six-month period ending December 31, 2025[85]. Accounting Standards - The company adopted all new and revised accounting standards effective from July 1, 2025, with no significant impact on the financial statements[15]. - The company did not early adopt any new or revised Hong Kong Financial Reporting Standards that have been issued but are not yet effective[16].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Sinopharm Tech Holdings Limited 國藥科技股份有限公司 ( 於開曼群島註冊成立之有限公司 ) (股份代號: 8156) 董事會會議日期 方面均準確完備，沒有誤導或欺詐成分，且並無遺漏任何事項，足以令致本公告 或其所載任何陳述產生誤導。 郭淑儀 香港，二零二六年二月十一日 於本公告日期，董事會由執行董事趙善能先生及郭淑儀女士，以及獨立非執行董 事劉斐先生、向碧倫先生、刁志強先生及余秉明先生組成。 本公告的資料乃遵照香港聯合交易所有限公司的 GEM 證券上市規則而刊載，旨 在提供有關本公司的資料，董事願就本公告的資料共同及個別地承擔全部責任。 各董事在作出一切合理查詢後，確認就其所知及所信，本公告所載資料在各重要 -1- 國藥科技股份有限公司（「本公司」）董事會（「董事會」）宣佈本公司將於二 零二六年二月二十六日（星期四）舉行董事會會議，藉以（其中包括）批准本公 司及其附屬公司截 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 國藥科技股份有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08156 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 12,800,000,000 | HKD | | 0.0125 | HKD | | 160,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 12,800,000,000 | HKD | | 0.0125 | HKD | | 160,000,000 | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 國藥科技股份有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08156 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 12,800,000,000 | HKD | | 0.0125 | HKD | | 160,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 12,800,000,000 | HKD | | 0.0125 | HKD | | 160,000,000 | | ...

Group 1 - Dr. Cheng Yanjie has resigned as a non-executive director of the company following the conclusion of the annual general meeting [1] - Mr. Diao Zhiqiang and Mr. Yu Bingming have been elected as independent non-executive directors by the shareholders at the annual general meeting [1] - Mr. Xu Dong'an has resigned as an independent non-executive director due to other business commitments, effective from December 19, 2025 [1] Group 2 - Changes to the board committee composition will take effect from December 19, 2025, following the annual general meeting [1] - Mr. Xu has resigned as the chairman of the nomination committee and as a member of the audit committee, remuneration committee, and nomination committee [1] - Ms. Guo Shuyi has been appointed as a member of the remuneration committee and nomination committee [1] - Mr. Liu Fei has been appointed as the chairman and a member of the nomination committee [1] - Mr. Diao has been appointed as a member of the audit committee, remuneration committee, and nomination committee [1] - Mr. Yu has been appointed as a member of the audit committee and nomination committee [1]

Core Viewpoint - China National Pharmaceutical Technology Corporation (国药科技股份) announced changes in its board of directors following the annual general meeting, including the resignation and appointment of several independent non-executive directors [1] Group 1: Board Changes - Dr. Cheng Yanjie has retired as a non-executive director of the company after the annual general meeting [1] - Mr. Diao Zhiqiang and Mr. Yu Bingming were elected as independent non-executive directors by the shareholders during the annual general meeting [1] - Mr. Xu Dong'an has resigned as an independent non-executive director due to other business commitments, effective from December 19, 2025 [1] Group 2: Committee Composition Changes - Following the resignation of Mr. Xu, several changes to the board committees will take effect from December 19, 2025: - Mr. Xu has stepped down as the chairman of the nomination committee and as a member of the audit committee, remuneration committee, and nomination committee [1] - Ms. Guo Shuyi has been appointed as a member of the remuneration committee and nomination committee [1] - Mr. Liu Fei has been appointed as the chairman and a member of the nomination committee [1] - Mr. Diao has been appointed as a member of the audit committee, remuneration committee, and nomination committee [1] - Mr. Yu has been appointed as a member of the audit committee and remuneration committee [1]

Core Viewpoint - The announcement from China National Pharmaceutical Group Technology Co., Ltd. (08156.HK) indicates the resignation of independent non-executive director Xu Dong'an due to other business matters, effective after the shareholders' annual meeting on December 19, 2025 [1] Group 1 - The board of directors has confirmed the resignation of Xu Dong'an [1] - The effective date of the resignation is set for December 19, 2025, following the conclusion of the shareholders' annual meeting [1]